Filtered By:
Education: Study
Procedure: Percutaneous Coronary Intervention
This page shows you your search results in order of relevance. This is page number 19.
Order by Relevance | Date
Total 2305 results found since Jan 2013.
The Feasibility and Long-Term Outcomes of the Crossboss/Stingray for Treating Coronary Chronic Total Occlusions Lesions with Distal Diffuse Disease Landing Zone
CONCLUSIONS: In CTO lesions with distal diffuse disease landing zone, the technical success rates of CrossBoss/Stingray and the long-term clinical outcomes were not significantly different between the moderate stenosis group (50%-70%) and the severe stenosis group (>70%). However, the relatively high rate of long-term clinical outcomes, especially any revascularization, warrants further investigations on this indication in future studies.PMID:35345280 | DOI:10.31083/j.rcm2303113
Source: Reviews in Cardiovascular Medicine - March 29, 2022 Category: Cardiology Authors: Rutao Wang Genrui Chen Fangjun Mou Yi Liu Zhiyong Yin Bo Wang Haokao Gao Chao Gao Ling Tao Chengxiang Li Source Type: research
Ticagrelor with and without aspirin in patients with a prior coronary artery bypass graft undergoing percutaneous coronary intervention: the TWILIGHT-CABG study
CONCLUSIONS: In high-risk patients with prior CABG, ticagrelor monotherapy reduced bleeding without compromising ischaemic outcomes compared with ticagrelor plus aspirin.PMID:35979636 | DOI:10.4244/EIJ-D-22-00319
Source: EuroIntervention - August 18, 2022 Category: Cardiovascular & Thoracic Surgery Authors: Gennaro Sardella Frans J Beerkens George Dangas Davide Cao Usman Baber Samantha Sartori David J Cohen Carlo Briguori Robert Gil Johny Nicolas Zhongjie Zhang Dariusz Dudek Vijay Kunadian Ran Kornowski Giora Weisz Bimmer Claessen Steven O Marx Javier Escane Source Type: research
The Feasibility and Long-Term Outcomes of the Crossboss/Stingray for Treating Coronary Chronic Total Occlusions Lesions with Distal Diffuse Disease Landing Zone
CONCLUSIONS: In CTO lesions with distal diffuse disease landing zone, the technical success rates of CrossBoss/Stingray and the long-term clinical outcomes were not significantly different between the moderate stenosis group (50%-70%) and the severe stenosis group (>70%). However, the relatively high rate of long-term clinical outcomes, especially any revascularization, warrants further investigations on this indication in future studies.PMID:35345280 | DOI:10.31083/j.rcm2303113
Source: Reviews in Cardiovascular Medicine - March 29, 2022 Category: Cardiology Authors: Rutao Wang Genrui Chen Fangjun Mou Yi Liu Zhiyong Yin Bo Wang Haokao Gao Chao Gao Ling Tao Chengxiang Li Source Type: research
